Aurora Cannabis Inc. (ACB)
NASDAQ: ACB · Real-Time Price · USD
4.170
-0.050 (-1.18%)
Sep 24, 2026, 12:28 PM EDT - Market open
Aurora Cannabis Revenue
Aurora Cannabis had revenue of 67.55M CAD in the quarter ending June 30, 2026, a decrease of -8.80%. This brings the company's revenue in the last twelve months to 314.07M, up 12.35% year-over-year. In the fiscal year ending March 31, 2026, Aurora Cannabis had annual revenue of 320.59M with 10.97% growth.
Revenue (ttm)
314.07M CAD
Revenue Growth
+12.35%
P/S Ratio
1.24
Revenue / Employee
305,517 CAD
Employees
1,028
Market Cap
273.34M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 320.59M | 31.68M | 10.97% |
| Mar 31, 2025 | 288.91M | 19.27M | 7.15% |
| Mar 31, 2024 | 269.64M | 45.83M | 20.48% |
| Mar 31, 2023 | 223.80M | 2.47M | 1.11% |
| Jun 30, 2022 | 221.34M | -23.91M | -9.75% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Emergent BioSolutions | 770.20M |
| Organogenesis Holdings | 457.45M |
| Akebia Therapeutics | 219.06M |
| Organigram Global | 217.71M |
| Canopy Growth | 206.77M |
| Lifecore Biomedical | 129.46M |
| Anika Therapeutics | 120.65M |
| Journey Medical | 68.18M |
ACB News
- 18 hours ago - Aurora files application with ASC over Curaleaf bid deficiencies - TheFly
- 18 hours ago - Aurora Cannabis Files Application with Alberta Securities Commission to Protect Company Shareholders Having Identified Several Deficiencies in Curaleaf's Hostile Bid Disclosure - PRNewsWire
- 8 days ago - Aurora Cannabis reaffirms Q2 guidance guidance for sequential growth in revenue - TheFly
- 8 days ago - Aurora Cannabis Provides Business Update; Accretive Acquisition of Safari Flower Company and Leading European Performance Expected to Fuel International Growth in the Fiscal Second Quarter 2027 and Beyond - PRNewsWire
- 8 days ago - Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid - MarketBeat
- 9 days ago - Curaleaf Urges Aurora Shareholders To Back Bid, Seeks Halt To ATM Program - Nasdaq
- 9 days ago - Curaleaf urges Aurora Cannabis shareholders to accept its offer - TheFly
- 9 days ago - Aurora refutes Curaleaf’s ‘latest attempt to distract shareholders from facts’ - TheFly